Su Hui, Kang Qian, Wang Haihong, Yin Hui, Duan Linghui, Liu Yuli, Fan Ruying
Department of Gastroenterology, PLA Army General Hospital, Beijing 100700, P.R. China.
Exp Ther Med. 2018 Oct;16(4):2999-3003. doi: 10.3892/etm.2018.6559. Epub 2018 Aug 2.
This study investigated the effect of glucocorticoids combined with probiotics on inflammatory factors and intestinal microflora in the treatment of Crohn's disease. Eighty-three patients with Crohn's disease were selected from March 2015 to December 2017 in PLA Army General Hospital (Beijing, China). A total of 83 patients were randomly divided into the control group and treatment group. Patients in the control group were treated with routine treatment of oral sulfasalazine. Besides oral sulfasalazine, patients in the treatment group were treated with probiotics combined with glucocorticoids. At the same time, a total of 40 healthy individuals were selected to serve as the healthy group (received no treatment). Clinical efficacy, changes of inflammatory factors, incidence of infection and changes of intestinal flora were compared between the different groups. After treatment, the levels of inflammatory factors in both groups significantly decreased, and the reduction in the treatment group significantly increased than that in the control group (P<0.05). The levels of inflammatory cytokines in the treatment group reached the levels of that in the healthy individuals after treatment. After treatment, the levels of yeast, and of the two groups of patients were significantly decreased, while the level of was significantly increased, and the changes were more significant in the treatment group than those in the control group. After treatment, the number of intestinal flora in the treatment group reached that of the healthy individuals. Treatment efficiency of the treatment group was significantly higher than that of the control group, and the infection rate of the control group was significantly higher than that of the treatment group (P<0.05). The use of probiotics combined with glucocorticoid in the treatment of Crohn's disease can improve clinical curative effect, reduce the secretion of inflammatory factors and improve the level of intestinal flora, so as to achieve better outcomes compared with conventional method.
本研究探讨糖皮质激素联合益生菌治疗克罗恩病对炎症因子及肠道菌群的影响。选取2015年3月至2017年12月在中国人民解放军总医院(北京)就诊的83例克罗恩病患者。83例患者随机分为对照组和治疗组。对照组患者采用口服柳氮磺胺吡啶常规治疗。治疗组患者除口服柳氮磺胺吡啶外,采用益生菌联合糖皮质激素治疗。同时,选取40例健康个体作为健康组(未接受治疗)。比较不同组之间的临床疗效、炎症因子变化、感染发生率及肠道菌群变化。治疗后,两组炎症因子水平均显著降低,且治疗组降低幅度显著大于对照组(P<0.05)。治疗组炎症细胞因子水平治疗后达到健康个体水平。治疗后,两组患者酵母及[此处原文缺失部分内容]水平显著降低,而[此处原文缺失部分内容]水平显著升高,且治疗组变化比对照组更显著。治疗后,治疗组肠道菌群数量达到健康个体水平。治疗组治疗有效率显著高于对照组,对照组感染率显著高于治疗组(P<0.05)。益生菌联合糖皮质激素治疗克罗恩病可提高临床疗效,减少炎症因子分泌,改善肠道菌群水平,与传统方法相比可取得更好的治疗效果。